Applications
Thanks to the specific technology developed by ERYtech Pharma, a powerful platform has been validated:
  • to develop new products with long circulating action with no release of the compounds : bio-reaction into the red cells for Graspa®, oxygen-hemoglobin affinity reduction for Grara.
  • to rapidly target specific cells involved in the erythrophagocytosis (Kupffer cells, dendritic cells, macrophages) : intra cells gene silencing for Gr- Rnai, in situ immuno-stimulation of dendritic cells for GrVax.

 

Erytech Pharma
Last Update 04/03/2010
2005 ERYtech Inc. All Rights Reserved | Terms and Conditions | Contact Us